Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05759143

Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing

This research is being done to develop the electronic platform Nest for young adults (ages 18-39) who have had prior cancer genetic testing. The platform will give patients and their clinicians access to continuously updated information about both pathogenic variants and variants of uncertain significance (VUS).

The name of the intervention used in this research study is:

Nest portal (electronic platform for patients and clinicians)

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–39 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States

Location status: Recruiting

Location contact

Jennifer Mack, MD

CONTACT

[email protected]

(617) 632-6622

Jennifer Mack, MD

PRINCIPAL_INVESTIGATOR

About this study

The goal of the electronic platform Nest is to help patients understand and manage genetic test results and recommended care and to help clinicians with access to results and recommendations, facilitating orders, and documentation. The portal has two parts, one for participants and one for clinicians.

For the first phase of the study, participants will give their feedback on the Nest portal's content and processes that will guide refinement of the portal. The Pilot phase will test the feasibility and acceptability of the intervention.

The research study procedures include a baseline survey, using the portal after receiving a brief orientation from the study team, a follow-up survey, and then a 30-minute interview.

Participants will be in this research study for up to 2 hours.

It is expected that about 40 people will take part in this research study.

The electronic platform is being developed by Nest Genomics.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

AIM 1:

  • YA Patients:
  • Ages 18-39 years, inclusive.
  • Has had previous cancer genetic testing, with a finding of a pathogenic variant or VUS; patient has previously received results from the clinical team.
  • English-speaking and -reading.
  • Receiving care at DFCI.
  • Not undergoing active cancer therapy at the time of approach.
  • Clinicians:
  • Cancer risk physicians (oncologists, gastroenterologists, geneticists), oncologists, nurse practitioners, physician assistants, or genetic counselors.
  • English-speaking and -reading.
  • Cares for YAs aged 18-39 with cancer risk syndromes.

Inclusion criteria

AIM 2:

  • YA Patients:
  • Ages 18-39 years, inclusive.
  • Has had previous cancer genetic testing, with a finding of a pathogenic variant or VUS; patient has previously received results from the clinical team.
  • English-speaking and -reading.
  • Receiving care at Dana-Farber Cancer Institute.
  • Did not participate in a stakeholder interview (Aim 1).
  • Not undergoing active cancer therapy at the time of approach.
  • Clinicians:
  • Oncologists, nurse practitioners, cancer risk physicians, or genetic counselors.
  • English-speaking and -reading.
  • Caring for a participating YA.

Treatment and study plan

Nest Platform

Behavioral

Patient- and clinician-facing portal via secure link

Primary outcomes

  1. Proportion of Participant Utilization (Feasibility)

    Time frame: 2 hours

    Defined as > 70% of consenting participants who use the intervention.

  2. Proportion of Clinician Utilization (Feasibility)

    Time frame: 2 hours

    Defined as > 70% of consenting clinicians who use the intervention.

  3. Proportion of Clinicians with FIM (Feasibility of Intervention Measure) Score > 4

    Time frame: At post-visit survey, up to 2 hours

    Defined as >70% of clinicians consider the intervention feasible as assessed by the post-visit survey.

  4. Proportion of Participants with AIM (Acceptability of Intervention Measure) Score > 4

    Time frame: At post-visit survey, up to 30 days

    Defined as > 70% of young adult participants consider the intervention successful as measured by a post-visit AIM score >4

  5. Proportion of Clinicians with AIM Score > 4

    Time frame: at post-visit survey, up to 2 hours

    Defined as > 70% of clinicians consider the intervention successful as measured by a post-visit AIM score >4

Secondary outcomes

  1. Change in knowledge of cancer risk

    Time frame: Baseline and post visit up to 2 hours

    Change in cancer knowledge will be assessed by participant survey at baseline and post visit.

  2. Change in Recommended screening

    Time frame: Baseline and post visit up to 2 hours

    Change in Recommended screening will be assessed by participant survey at baseline and post visit.

Study contacts

Contact information is provided by the study sponsor or research team.

Jennifer Mack, MD

CONTACT

[email protected]

617-632-6818

Sponsors and collaborators

Lead sponsor

Dana-Farber Cancer Institute

Other

Collaborators

  • Nest Genomics

Registry information

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Mar 8, 2023
Registry last updated
Apr 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.